Lauriane Eberst

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies and yet there are potential treatment options for patients after standard treatment escape. The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of patients treated with off-label TTs. Every(More)
  • 1